NCT02386397View on ClinicalTrials.gov

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
Digestive Cancer
Interventions
DRUG

Regorafenib

Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment

DRUG

GEMOX

mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine

Trial Locations (1)

34298

Centre Val d'Aurelle, Montpellier

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT02386397 - Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter